Famotidine-induced mixed hepatocellular jaundice.
OBJECTIVE
To report a case of probable famotidine-induced mixed hepatocellular jaundice.


METHODS
A 55-year-old man presented with a one-month history of mid-epigastric pain. Initial physical examination and laboratory studies, including liver enzyme concentration tests, were unrevealing. A diagnosis of gastritis was made and ranitidine was prescribed. Following one week of therapy, the patient's symptoms had not improved and therapy was changed to famotidine and sucralfate. Approximately one week later the patient presented with jaundice. Liver enzyme concentrations were elevated and the patient was hospitalized for further evaluation. Five days following discontinuation of famotidine, liver enzyme concentrations were normal and jaundice had resolved. Further tests did not reveal any pathologic etiology.


CONCLUSIONS
Hepatic changes have occurred in patients receiving histamine2-antagonists; ranitidine and cimetidine have been cited most frequently. In general, the elevations are mild, transient, and return to baseline with continued therapy. This is one of the first case reports of probable famotidine-induced mixed hepatocellular jaundice.


CONCLUSIONS
There was a temporal relationship between the patient's signs and symptoms and initiation of famotidine. No identifiable factors contributed to the elevated liver enzyme concentrations and jaundice.
Ament
P W
PW
Department of Pharmacy, Latrobe Area Hospital, PA 15650.
Roth
J D
JD
Fox
C J
CJ
D002780:Cholestasis, Intrahepatic / Q000139:chemically induced*; D015738:Famotidine / Q000009:adverse effects*; D006801:Humans; D008297:Male; D008875:Middle Aged
D015738:Famotidine